The drug does not cause an individual to become unconscious, merely to be sedated.[12] It is also useful for the treatment of prolonged (lasting over five minutes) seizures.[14] Midazolam can be given by mouth, intravenously, by injection into a muscle, by spraying into the nose, or through the cheek.[12][14] When given intravenously, it typically begins working within five minutes; when injected into a muscle, it can take fifteen minutes to begin working;[12] when taken orally, it can take 10–20 minutes to begin working.[15]
Side effects can include a decrease in efforts to breathe, low blood pressure, and sleepiness.[12]Tolerance to its effects and withdrawal syndrome may occur following long-term use.[16]Paradoxical effects, such as increased activity, can occur especially in children and older people.[16] There is evidence of risk when used during pregnancy but no evidence of harm with a single dose during breastfeeding.[17][18]
Midazolam is sometimes used for the acute management of prolonged seizures. Long-term use for the management of epilepsy is not recommended due to the significant risk of tolerance (which renders midazolam and other benzodiazepines ineffective) and the significant side effect of sedation.[21] A benefit of midazolam is that in children it can be given in the cheek or in the nose for acute seizures, including status epilepticus.[22][23]
Drawbacks include a high degree of breakthrough seizures—due to the short half-life of midazolam—in over 50% of people treated, as well as treatment failure in 14–18% of people with refractory status epilepticus. Tolerance develops rapidly to the anticonvulsant effect, and the dose may need to be increased by several times to maintain anticonvulsant therapeutic effects. With prolonged use, tolerance and tachyphylaxis can occur and the elimination half-life may increase, up to days.[16][24]Buccal and intranasal midazolam may be both easier to administer and more effective than rectally administered diazepam in the emergency control of seizures.[25][26][27]
Procedural sedation
Intravenous midazolam is indicated for procedural sedation (often in combination with an opioid, such as fentanyl), preoperative sedation, for the induction of general anesthesia, and for sedation of people who are ventilated in critical care units.[28][29] Midazolam is superior to diazepam in impairing memory of endoscopy procedures, but propofol has a quicker recovery time and a better memory-impairing effect.[30] It is the most popular benzodiazepine in the intensive care unit (ICU) because of its short elimination half-life, combined with its water solubility and its suitability for continuous infusion. However, for long-term sedation, lorazepam is preferred due to its long duration of action,[31] and propofol has advantages over midazolam when used in the ICU for sedation, such as shorter weaning time and earlier tracheal extubation.[32]
Midazolam is sometimes used in neonatal intensive care units. When used, additional caution is required in newborns; midazolam should not be used for longer than 72 hours due to risks of tachyphylaxis, and the possibility of development of a benzodiazepine withdrawal syndrome, as well as neurological complications. Bolus injections should be avoided due to the increased risk of cardiovascular depression, as well as neurological complications.[33]
Sedation using midazolam can be used to relieve anxiety and manage behaviour in children undergoing dental treatment.[34]
Agitation
Midazolam, in combination with an antipsychotic drug, is indicated for the acute management of schizophrenia when it is associated with aggressive or out-of-control behaviour.[35]
End of life care
In the final stages of end-of-life care, midazolam is routinely used at low doses via subcutaneous injection to help with agitation, restlessness or anxiety in the last hours or days of life.[36] At higher doses during the last weeks of life, midazolam is considered a first line agent in palliative continuous deep sedation therapy when it is necessary to alleviate intolerable suffering not responsive to other treatments,[37] but the need for this is rare.[38]
Routes of administration of midazolam can be oral, intranasal, buccal, intravenous, and intramuscular.
Dosing
Perioperative use
0.15 to 0.40 mg/kg IV
Premedication
0.07 to 0.10 mg/kg IM
Intravenous sedation
0.05 to 0.15 mg/kg IV
Contraindications
Benzodiazepines require special precaution if used in the elderly, during pregnancy, in children, in alcohol- or other drug-dependent individuals or those with comorbidpsychiatric disorders.[39] Additional caution is required in critically ill patients, as accumulation of midazolam and its active metabolites may occur.[40] Kidney or liver impairments may slow down the elimination of midazolam leading to prolonged and enhanced effects.[41][42]
Side effects of midazolam in the elderly are listed above.[16] People experiencing amnesia as a side effect of midazolam are generally unaware their memory is impaired, unless they had previously known it as a side effect.[43]
Long-term use of benzodiazepines has been associated with long-lasting deficits in memory, and show only partial recovery six months after stopping benzodiazepines.[16] It is unclear whether full recovery occurs after longer periods of abstinence. Benzodiazepines can cause or worsen depression.[16] Paradoxical excitement occasionally occurs with benzodiazepines, including a worsening of seizures. Children and elderly individuals or those with a history of excessive alcohol use and individuals with a history of aggressive behavior or anger are at increased risk of paradoxical effects.[16]Paradoxical reactions are particularly associated with intravenous administration.[44] After nighttime administration of midazolam, residual 'hangover' effects, such as sleepiness and impaired psychomotor and cognitive functions, may persist into the next day. This may impair the ability of users to drive safely and may increase the risk of falls and hip fractures.[45] Sedation, respiratory depression and hypotension due to a reduction in systematic vascular resistance, and an increase in heart rate can occur.[23][41] If intravenous midazolam is given too quickly, hypotension may occur. A "midazolam infusion syndrome" may result from high doses, is characterised by delayed arousal hours to days after discontinuation of midazolam, and may lead to an increase in the length of ventilatory support needed.[46]
In rare susceptible individuals, midazolam has been known to cause a paradoxical reaction, a well-documented complication with benzodiazepines. When this occurs, the individual may experience anxiety, involuntary movements, aggressive or violent behavior, uncontrollable crying or verbalization, and other similar effects. This seems to be related to the altered state of consciousness or disinhibition produced by the drug. Paradoxical behavior is often not recalled by the patient due to the amnesia-producing properties of the drug. In extreme situations, flumazenil can be administered to inhibit or reverse the effects of midazolam. Antipsychotic medications, such as haloperidol, have also been used for this purpose.[47]
Midazolam is known to cause respiratory depression. In healthy humans, 0.15 mg/kg of midazolam may cause respiratory depression, which is postulated to be a central nervous system (CNS) effect.[48] When midazolam is administered in combination with fentanyl, the incidence of hypoxemia or apnea becomes more likely.[49]
Although the incidence of respiratory depression/arrest is low (0.1–0.5%) when midazolam is administered alone at normal doses,[50][51] the concomitant use with CNS acting drugs, mainly analgesic opiates, may increase the possibility of hypotension, respiratory depression, respiratory arrest, and death, even at therapeutic doses.[49][50][52][53] Potential drug interactions involving at least one CNS depressant were observed for 84% of midazolam users who were subsequently required to receive the benzodiazepine antagonist flumazenil.[54] Therefore, efforts directed toward monitoring drug interactions and preventing injuries from midazolam administration are expected to have a substantial impact on the safe use of this drug.[54]
Pregnancy and breastfeeding
Midazolam, when taken during the third trimester of pregnancy, may cause risk to the neonate, including benzodiazepine withdrawal syndrome, with possible symptoms including hypotonia, apnoeic spells, cyanosis, and impaired metabolic responses to cold stress. Symptoms of hypotonia and the neonatal benzodiazepine withdrawal syndrome have been reported to persist from hours to months after birth.[55] Other neonatal withdrawal symptoms include hyperexcitability, tremor, and gastrointestinal upset (diarrhea or vomiting). Breastfeeding by mothers using midazolam is not recommended.[56]
Elderly
Additional caution is required in the elderly, as they are more sensitive to the pharmacological effects of benzodiazepines, metabolise them more slowly, and are more prone to adverse effects, including drowsiness, amnesia (especially anterograde amnesia), ataxia, hangover effects, confusion, and falls.[16]
Tolerance, dependence, and withdrawal
A benzodiazepine dependence occurs in about one-third of individuals who are treated with benzodiazepines for longer than 4 weeks,[16] which typically results in tolerance and benzodiazepine withdrawal syndrome when the dose is reduced too rapidly. Midazolam infusions may induce tolerance and a withdrawal syndrome in a matter of days. The risk factors for dependence include dependent personality, use of a benzodiazepine that is short-acting, high potency and long-term use of benzodiazepines. Withdrawal symptoms from midazolam can range from insomnia and anxiety to seizures and psychosis. Withdrawal symptoms can sometimes resemble a person's underlying condition. Gradual reduction of midazolam after regular use can minimise withdrawal and rebound effects. Tolerance and the resultant withdrawal syndrome may be due to receptor down-regulation and GABAA receptor alterations in gene expression, which causes long-term changes in the function of the GABAergic neuronal system.[16][57][58]
Chronic users of benzodiazepine medication who are given midazolam experience reduced therapeutic effects of midazolam, due to tolerance to benzodiazepines.[46][59] Prolonged infusions with midazolam results in the development of tolerance; if midazolam is given for a few days or more a withdrawal syndrome can occur. Therefore, preventing a withdrawal syndrome requires that a prolonged infusion be gradually withdrawn, and sometimes, continued tapering of dose with an oral long-acting benzodiazepine such as clorazepate dipotassium. When signs of tolerance to midazolam occur during intensive care unit sedation the addition of an opioid or propofol is recommended. Withdrawal symptoms can include irritability, abnormal reflexes, tremors, clonus, hypertonicity, delirium and seizures, nausea, vomiting, diarrhea, tachycardia, hypertension, and tachypnea.[46]
A midazolam overdose is considered a medical emergency and generally requires the immediate attention of medical personnel. Benzodiazepine overdose in healthy individuals is rarely life-threatening with proper medical support; however, the toxicity of benzodiazepines increases when they are combined with other CNS depressants such as alcohol, opioids, or tricyclic antidepressants. The toxicity of benzodiazepine overdose and the risk of death are also increased in the elderly and those with obstructive pulmonary disease or when used intravenously. Treatment is supportive; activated charcoal can be used within an hour of the overdose. The antidote for an overdose of midazolam (or any other benzodiazepine) is flumazenil.[41] While effective in reversing the effects of benzodiazepines it is not used in most cases as it may trigger seizures in mixed overdoses and benzodiazepine dependent individuals.[60][61]
Symptoms of midazolam overdose can include:[60][61]
Concentrations of midazolam or its major metabolite, 1-hydroxymidazolam glucuronide, may be measured in plasma, serum, or whole blood to monitor for safety in those receiving the drug therapeutically, to confirm a diagnosis of poisoning in hospitalized patients, or to assist in a forensic investigation of a case of fatal overdosage. Patients with renal dysfunction may exhibit prolongation of elimination half-life for both the parent drug and its active metabolite, with accumulation of these two substances in the bloodstream and the appearance of adverse depressant effects.[62]
Midazolam is a short-acting benzodiazepine in adults with an elimination half-life of 1.5–2.5 hours.[13] In the elderly, as well as young children and adolescents, the elimination half-life is longer.[44][66] Midazolam is metabolised into an active metabolite alpha-hydroxymidazolam. Age-related deficits, renal and liver status affect the pharmacokinetic factors of midazolam as well as its active metabolite.[67] However, the active metabolite of midazolam is minor and contributes to only 10% of biological activity of midazolam. Midazolam is poorly absorbed orally, with only 50% of the drug reaching the bloodstream.[16] Midazolam is metabolised by cytochrome P450 (CYP) enzymes and by glucuronide conjugation. Oxidation of midazolam is the major metabolite in human liver microsome (HLM).[68] The half life (t1⁄2) of midazolam in HLM is 3.3 minutes.[68] The therapeutic as well as adverse effects of midazolam are due to its effects on the GABAA receptors; midazolam does not activate GABAA receptors directly but, as with other benzodiazepines, it enhances the effect of the endogenous neurotransmitter GABA on the GABAA receptors (increasing the frequency of Cl− channel opening) resulting in neural inhibition. Almost all of the properties can be explained by the actions of benzodiazepines on GABAA receptors. This results in the following pharmacological properties being produced: sedation, induction of sleep, reduction in anxiety, anterograde amnesia, muscle relaxation and anticonvulsant effects.[41]
History
Midazolam is among about 35 benzodiazepines currently used medically,[69] and was synthesized in 1975 by Walser and Fryer at Hoffmann-LaRoche, Inc in the United States.[70] Owing to its water solubility, it was found to be less likely to cause thrombophlebitis than similar drugs.[71][72] The anticonvulsant properties of midazolam were studied in the late 1970s, but not until the 1990s did it emerge as an effective treatment for convulsive status epilepticus.[73] As of 2010[update], it is the most commonly used benzodiazepine in anesthetic medicine.[74] In acute medicine, midazolam has become more popular than other benzodiazepines, such as lorazepam and diazepam, because it is shorter lasting, is more potent, and causes less pain at the injection site.[69] Midazolam is also becoming increasingly popular in veterinary medicine due to its water solubility.[75] In 2018 it was revealed the CIA considered using midazolam as a "truth serum" on terrorist suspects in project "Medication".[76]
Society and culture
Cost
Midazolam is available as a generic medication.[17]
Availability
Midazolam is available in the United States as a syrup or as an injectable solution.[77]
Dormicum brand midazolam is marketed by Roche as white, oval, 7.5 mg tablets in boxes of two or three blister strips of 10 tablets, and as blue, oval, 15 mg tablets in boxes of two (Dormonid 3x) blister strips of 10 tablets. The tablets are imprinted with "Roche" on one side and the dose of the tablet on the other side. Dormicum is also available as 1, 3, and 10 mL ampoules at a concentration of 5 mg/mL. Another manufacturer, Novell Pharmaceutical Laboratories, makes it available as Miloz in 3 and 5 mL ampoules. Midazolam is the only water-soluble benzodiazepine available. Another maker is Roxane Laboratories; the product in an oral solution, midazolam HCl Syrup, 2 mg/mL clear, in a red to purplish-red syrup, cherry in flavor. It becomes soluble when the injectable solution is buffered to a pH of 2.9–3.7. Midazolam is also available in liquid form.[16] It can be administered intramuscularly,[23]intravenously,[78]intrathecally,[79]intranasally,[26]buccally,[80] or orally.[16]
Legal status
In the Netherlands, midazolam is a List II drug of the Opium Law.
Midazolam is a Schedule IV drug under the Convention on Psychotropic Substances.[81] In the United Kingdom, midazolam is a Schedule 3/Class C controlled drug.[82] In the United States, midazolam (DEA number 2884) is on the Schedule IV list of the Controlled Substances Act as a non-narcotic agent with low potential for abuse.[83]
Marketing authorization
In 2011, the European Medicines Agency (EMA) granted a marketing authorisation for a buccal application form of midazolam, sold under the brand name Buccolam.[9] Buccolam was initially approved for the treatment of prolonged, acute, convulsive seizures in people from three months to less than 18 years of age.[9] This is the first application of a paediatric-use marketing authorisation by the EMA.[84][85]
Use in executions
The drug has been introduced for use in executions by lethal injection in certain jurisdictions in the United States in combination with other drugs. It was introduced to replace pentobarbital after the latter's manufacturer disallowed that drug's use for executions.[86] Midazolam acts as a sedative, resulting in the prisoner being in a state of deep anesthesia comparable to that experienced during surgery. One or more other drugs are usually used to stop the prisoner's heart, rendering them medically dead.
Midazolam has been used as part of a three-drug cocktail with vecuronium bromide and potassium chloride in Florida and Oklahoma prisons[87] and has also been used along with hydromorphone in a two-drug protocol in Ohio and Arizona.[87]
Notable incidents
The state of Florida used midazolam to execute William Frederick Happ in October 2013.[88]
The state of Ohio used midazolam in the execution of Dennis McGuire in January 2014; he was heavily anesthetized and unconscious within 4 minutes of starting the administration of midazolam and 20 more minutes after that point before he was declared medically dead. Controversy arose after he was observed gasping and appeared to choke during that time according to reporters who were allowed to be present, leading to questions about the dosing and timing of the drug administration, as well as the choice of drugs.[89]
The usage of midazolam in executions became controversial after condemned inmate Clayton Lockett apparently regained consciousness and started speaking midway through his 2014 execution when the state of Oklahoma attempted to execute him with an untested three-drug lethal injection combination including 100mg of midazolam. Prison officials reportedly discussed taking him to a hospital before he was pronounced dead of a heart attack 40 minutes after the execution began. An observing doctor stated that Lockett's vein had ruptured. It is not clear whether his death was caused by one or more of the drugs or by a problem in the administration procedure, nor is it clear what quantities of vecuronium bromide and potassium chloride were released to his system before the execution was cancelled.[90][91]
According to news reports, the execution of Ronald Bert Smith in the state of Alabama on 8 December 2016 allegedly went awry due to the fact he displayed movement soon after midazolam was injected, although prison staff confirmed twice that he was still unconscious before injecting the two fatal drugs.[92] This controversy again stirred concern among the public regarding the effectiveness of the drug in question.[86]
In October 2016, the state of Ohio announced that it would resume executions in January 2017, using a formulation of midazolam, vecuronium bromide, and potassium chloride, but this was blocked by a federal judge.[93][94] On 26 July 2017, Ronald Phillips was executed with a three-drug cocktail including midazolam after the Supreme Court refused to grant a stay.[95] Prior to this, the last execution in Ohio had been that of Dennis McGuire.[96] Murderer Gary Otte's lawyers unsuccessfully challenged his Ohio execution, arguing that midazolam might not protect him from serious pain when the other drugs are administered. He died without incident in about 14 minutes on 13 September 2017.[97]
In April 2017, the state of Arkansas carried out a double-execution, of Jack Harold Jones, 52, and Marcel Williams, 46. Arkansas attempted to execute eight people before its supply of midazolam expired on 30 April 2017. Two of them were granted a stay of execution, and another, Ledell Lee, 51, was executed on 20 April 2017.[98]
In October 2021, the state of Oklahoma executed inmate John Marion Grant, 60, using midazolam as part of its three-drug cocktail hours after the U.S. Supreme Court ruled to lift a stay of execution for Oklahoma death row inmates. The execution was the state's first since 2015. Witnesses to the execution said that when the first drug, midazolam, began to flow at 4:09p.m., Grant started convulsing about two dozen times and vomited. Grant continued breathing, and a member of the execution team wiped the vomit off his face. At 4:15p.m., officials said Grant was unconscious, and he was pronounced dead at 4:21p.m.[99]
Legal challenges
In Glossip v. Gross, attorneys for three Oklahoma inmates argued that midazolam could not achieve the level of unconsciousness required for surgery, meaning severe pain and suffering was likely. They argued that midazolam was cruel and unusual punishment and thus contrary to the Eighth Amendment to the United States Constitution. In June 2015, the U.S. Supreme Court ruled that they had failed to prove that midazolam was cruel and unusual when compared to known, available alternatives.[100]
The state of Nevada is also known to use midazolam in execution procedures. In July 2018, one of the manufacturers accused state officials of obtaining the medication under pretences. This incident was the first time a drug company successfully, though temporarily, halted an execution.[101] A previous attempt in 2017, to halt an execution in the state of Arizona by another drug manufacturer was not successful.[102]
^Johnson TN, Rostami-Hodjegan A, Goddard JM, Tanner MS, Tucker GT (September 2002). "Contribution of midazolam and its 1-hydroxy metabolite to preoperative sedation in children: a pharmacokinetic-pharmacodynamic analysis". British Journal of Anaesthesia. 89 (3): 428–437. doi:10.1093/bja/aef213. PMID12402721.
^ abBrigo F, Nardone R, Tezzon F, Trinka E (August 2015). "Nonintravenous midazolam versus intravenous or rectal diazepam for the treatment of early status epilepticus: A systematic review with meta-analysis". Epilepsy & Behavior. 49: 325–336. doi:10.1016/j.yebeh.2015.02.030. PMID25817929. S2CID33207030.
^World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.
^Isojärvi JI, Tokola RA (December 1998). "Benzodiazepines in the treatment of epilepsy in people with intellectual disability". Journal of Intellectual Disability Research. 42 (Suppl 1): 80–92. PMID10030438.
^Eriksson K, Kälviäinen R (November 2005). "Pharmacologic management of convulsive status epilepticus in childhood". Expert Review of Neurotherapeutics. 5 (6): 777–783. doi:10.1586/14737175.5.6.777. PMID16274335. S2CID2865644.
^ abWolfe TR, Macfarlane TC (May 2006). "Intranasal midazolam therapy for pediatric status epilepticus". The American Journal of Emergency Medicine. 24 (3): 343–346. doi:10.1016/j.ajem.2005.11.004. PMID16635708.
^Sofou K, Kristjánsdóttir R, Papachatzakis NE, Ahmadzadeh A, Uvebrant P (August 2009). "Management of prolonged seizures and status epilepticus in childhood: a systematic review". Journal of Child Neurology. 24 (8): 918–926. doi:10.1177/0883073809332768. PMID19332572. S2CID41731847.
^Brown TB, Lovato LM, Parker D (January 2005). "Procedural sedation in the acute care setting". American Family Physician. 71 (1): 85–90. PMID15663030.
^O'Connor M, Bucknall T, Manias E (May 2010). "Sedation management in Australian and New Zealand intensive care units: doctors' and nurses' practices and opinions". American Journal of Critical Care. 19 (3): 285–295. doi:10.4037/ajcc2009541. PMID19770414.
^McQuaid KR, Laine L (May 2008). "A systematic review and meta-analysis of randomized, controlled trials of moderate sedation for routine endoscopic procedures". Gastrointestinal Endoscopy. 67 (6): 910–923. doi:10.1016/j.gie.2007.12.046. PMID18440381.
^Arcangeli A, Antonelli M, Mignani V, Sandroni C (November 2005). "Sedation in PACU: the role of benzodiazepines". Current Drug Targets. 6 (7): 745–748. doi:10.2174/138945005774574416. PMID16305452.
^De Cosmo G, Congedo E, Clemente A, Aceto P (November 2005). "Sedation in PACU: the role of propofol". Current Drug Targets. 6 (7): 741–744. doi:10.2174/138945005774574425. PMID16305451.
^Rawicz M (October–December 2008). "[Recommendations for analgesia and sedation in neonatal intensive care]". Medycyna Wieku Rozwojowego. 12 (4 Pt 1): 958–967. PMID19471072.
^de Graeff A, Dean M (February 2007). "Palliative sedation therapy in the last weeks of life: a literature review and recommendations for standards". Journal of Palliative Medicine. 10 (1): 67–85. doi:10.1089/jpm.2006.0139. PMID17298256.
^Royal College of Physicians (September 2009). "National care of the dying audit 2009". United Kingdom. Archived from the original on 20 January 2010. Retrieved 10 February 2010. "[I]n their last 24 hours... 31% had low doses of medication to [control distress from agitation or restlessness]... the remaining 4% required higher doses"
^Authier N, Balayssac D, Sautereau M, Zangarelli A, Courty P, Somogyi AA, et al. (November 2009). "Benzodiazepine dependence: focus on withdrawal syndrome". Annales Pharmaceutiques Françaises. 67 (6): 408–413. doi:10.1016/j.pharma.2009.07.001. PMID19900604.
^Verbeeck RK (December 2008). "Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction". European Journal of Clinical Pharmacology. 64 (12): 1147–1161. doi:10.1007/s00228-008-0553-z. PMID18762933. S2CID27888650.
^Merritt P, Hirshman E, Hsu J, Berrigan M (January 2005). "Metamemory without the memory: are people aware of midazolam-induced amnesia?". Psychopharmacology. 177 (3): 336–343. doi:10.1007/s00213-004-1958-8. PMID15290003. S2CID7142863.
^ abClassen DC, Pestotnik SL, Evans RS, Burke JP (1992). "Intensive surveillance of midazolam use in hospitalized patients and the occurrence of cardiorespiratory arrest". Pharmacotherapy. 12 (3): 213–216. doi:10.1002/j.1875-9114.1992.tb04512.x. PMID1608855. S2CID42657347.
^Wright SW, Chudnofsky CR, Dronen SC, Wright MB, Borron SW (March 1990). "Midazolam use in the emergency department". The American Journal of Emergency Medicine. 8 (2): 97–100. doi:10.1016/0735-6757(90)90192-3. PMID2302291.
^Yaster M, Nichols DG, Deshpande JK, Wetzel RC (September 1990). "Midazolam-fentanyl intravenous sedation in children: case report of respiratory arrest". Pediatrics. 86 (3): 463–467. doi:10.1542/peds.86.3.463. PMID2388795. S2CID36531097.
^ abKawano DF, Ueta J, Sankarankutty AK, Pereira LR, de Freitas O (June 2009). "Midazolam-related drug interactions: detection of risk situations to the patient safety in a brazilian teaching hospital". Journal of Patient Safety. 5 (2): 69–74. doi:10.1097/PTS.0b013e3181a5dafa. PMID19920444. S2CID12973546.
^Serreau R (April 2010). "[Drugs during preeclampsia. Fetal risks and pharmacology]". Annales Françaises d'Anesthésie et de Réanimation. 29 (4): e37 –e46. doi:10.1016/j.annfar.2010.02.016. PMID20347563.
^Cho HH, O'Connell JP, Cooney MF, Inchiosa MA (2007). "Minimizing tolerance and withdrawal to prolonged pediatric sedation: case report and review of the literature". Journal of Intensive Care Medicine. 22 (3): 173–179. doi:10.1177/0885066607299556. PMID17569173. S2CID42497090.
^Baselt RC (2008). Disposition of Toxic Drugs and Chemicals in Man (8th ed.). Foster City CA: Biomedical Publications. pp. 1037–40. ISBN978-0-9626523-7-0.
^Arayne MS, Sultana N, Bibi Z (October 2005). "Grape fruit juice-drug interactions". Pakistan Journal of Pharmaceutical Sciences. 18 (4): 45–57. PMID16380358.
^Barash PG, Cullen BF, Stoelting RK, Cahalan MD (1 April 2009). Clinical Anesthesia (6th ed.). Lippincott Williams Wilkins. p. 588. ISBN978-0-7817-8763-5. Archived from the original on 20 February 2017.
^US patent 4166185, Walser A, Fryer RI, Benjamin L, "Imidazo[1,5-α] [1,4]benzodiazepines", published 1979-08-28, issued 1979-08-28, assigned to Hoffmann La Roche Inc.Archived 17 June 2022 at the Wayback Machine
^Kaplan JM, Reich DL, Lake CL, Konstadt SN (15 May 2006). Cardiac Anesthesia (5th ed.). W.B. Saunders Company. ISBN978-1-4160-0253-6.
^Steib A, Hausberger D, Robillart A, Roche A, Franckhauser D, Dupeyron JP (June 2006). "[Anaesthetic considerations for interventional radiology]". Annales Françaises d'Anesthésie et de Réanimation. 25 (6): 615–625. doi:10.1016/j.annfar.2006.01.018. PMID16632296.
هذه المقالة يتيمة إذ تصل إليها مقالات أخرى قليلة جدًا. فضلًا، ساعد بإضافة وصلة إليها في مقالات متعلقة بها. (ديسمبر 2020) أليثا سولتر معلومات شخصية الميلاد سنة 1945 (العمر 77–78 سنة) مواطنة الولايات المتحدة الحياة العملية المهنة عالمة نفس، وكاتِبة اللغات الإنجلي
Deputi Bidang Koordinasi Pariwisata dan Ekonomi Kreatif (Deputi V Kemenko Marves) merupakan unsur pelaksana pada Kementerian Koordinator Bidang Kemaritiman Republik Indonesia yang berada di bawah dan bertanggung jawab kepada Menteri Koordinator Bidang Kemaritiman dan Investasi. Deputi ini terbentuk berdasarkan Peraturan Presiden Nomor 92 Tahun 2019 tentang Kementerian Koordinator Bidang Kemaritiman dan Investasi. Deputi Bidang Koordinasi Koordinasi Pariwisata dan Ekonomi Kreatif mempunyai tug...
The 120 members of the twelfth Knesset were elected on 1 November 1988. The breakdown by party was as follows: Likud: 40 Alignment: 39 Shas: 6 Agudat Yisrael: 5 Ratz: 5 National Religious Party: 5 Hadash: 4 Tehiya: 3 Mapam: 3 Tzomet: 2 Moledet: 2 Shinui: 2 Degel HaTorah: 2 Progressive List for Peace: 1 Arab Democratic Party: 1 List of members Member Party Notes Aharon Abuhatzira Likud Shaul Amor Likud Moshe Arens Likud Benny Begin Likud Eliyahu Ben-Elissar Likud Yigal Cohen Likud Haim Corfu L...
село Майдан-Чапельський Країна Україна Область Вінницька область Район Вінницький район Громада Лука-Мелешківська сільська громада Код КАТОТТГ UA05020150040024572 Основні дані Засноване 1600 Населення 370 Площа 0,47 км² Густота населення 787,23 осіб/км² Поштовий індекс 23209 Теле
2007 single by The-DreamFalsettoSingle by The-Dreamfrom the album Love/Hate ReleasedSeptember 28, 2007Recorded2007GenreR&BLength4:31 (Album Version)4:06 (Radio/Video Edit)LabelRadio Killa/Def JamSongwriter(s)Terius Nash and Christopher StewartProducer(s)Christopher Tricky StewartThe-Dream singles chronology Shawty Is a 10 (2007) Falsetto (2007) I Luv Your Girl (2008) Falsetto is the second single from The-Dream's debut studio album, Love/Hate.[1] The song is produced by Christophe...
عكده السرة (محلة) تقسيم إداري البلد اليمن المحافظة محافظة إب المديرية مديرية المخادر العزلة عزلة بضعة القرية قرية بيت سليم السكان التعداد السكاني 2004 السكان 28 • الذكور 15 • الإناث 13 • عدد الأسر 1 • عدد المساكن 4 معلومات أخرى التوقيت توقيت اليمن (+3 غرينيتش) تع
Governing body of association football in Greece Hellenic Football FederationUEFAShort nameHFFFounded14 November 1926; 97 years ago (1926-11-14)HeadquartersNea SmyrniFIFA affiliation1927UEFA affiliation1954PresidentTakis BaltakosWebsiteepo.gr The Hellenic Football Federation (HFF), also known as the Greek Football Federation (Greek: Ελληνική Ποδοσφαιρική Ομοσπονδία; ΕΠΟ, romanized: Ellinikí Podosferikí Omospondía; EPO), is the governi...
Молдова та Європейський Союз ЄС Молдова Ця стаття про відносини між Європейським Союзом і Республіка Молдова. Про процес переговорів про вступ див. Вступ Молдови до Європейського Союзу. Відносини між Молдовою та Європейським Союзом (ЄС) у даний час регулюються Європейсь...
English actress (1907–1981) Jessie MatthewsOBEMatthews in 1917, aged ten.BornJessie Margaret Matthews(1907-03-11)11 March 1907Soho, London, EnglandDied19 August 1981(1981-08-19) (aged 74)Eastcote, London, EnglandOccupationsActresssingerdancerYears active1919–1981Spouses Henry Lytton Jr. (m. 1926; div. 1930) Sonnie Hale (m. 1931; div. 1944) Brian Lewis (m...
American tennis player For the American landscape painter, see Willis E. Davis (painter). Willis E. DavisDavis in 1916Full nameWillis Elphinstone Davis Jr.Country (sports)United StatesBorn16 December 1893San Francisco, California, United StatesDied15 December 1936 (aged 42)[1]Fort Whipple, Arizona, United StatesHeight5 ft 11 in (1.80 m)[2]Retired1923CollegeUniversity of California, BerkeleyUniversity of PennsylvaniaSinglesHighest rankingNo. 9 (191...
Boys of Steel: The Creators of Superman AuthorMarc Tyler NoblemanIllustratorRoss MacDonaldCover artistRoss MacDonaldCountryUnited StatesLanguageEnglishSubjectChildren's, biographyGenreJuvenile nonfictionPublisherKnopf Books for Young Readers (an imprint of Random House Children's Books)Publication dateJuly 22, 2008Media typePrint (Hardback)Pages40ISBN978-0-375-83802-6 Boys of Steel: The Creators of Superman is a picture book written by Marc Tyler Nobleman and illustrated by Ross Mac...
Common name for two genera of wasps Tarantula hawk male Pepsis Scientific classification Domain: Eukaryota Kingdom: Animalia Phylum: Arthropoda Class: Insecta Order: Hymenoptera Family: Pompilidae Subfamily: Pepsinae Tribe: Pepsini Genera Pepsis Hemipepsis A tarantula hawk is a spider wasp (Pompilidae) that preys on tarantulas. Tarantula hawks belong to any of the many species in the genera Pepsis and Hemipepsis. They are one of the largest parasitoid wasps, using their sting to paralyze thei...
American rabbi (1857–1924)This article's lead section may be too short to adequately summarize the key points. Please consider expanding the lead to provide an accessible overview of all important aspects of the article. (November 2023)Henry BerkowitzBornMarch 18, 1857Pittsburgh, PennsylvaniaDiedFebruary 7, 1924Atlantic City, New Jersey Henry Berkowitz (March 18, 1857 – February 7, 1924) was a Reform rabbi, educator and author. Early life and education Henry Berkowitz was born in Pittsbur...
This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these template messages) This article may need to be rewritten to comply with Wikipedia's quality standards. You can help. The talk page may contain suggestions. (August 2023) This article may require copy editing for grammar, style, cohesion, tone, or spelling. You can assist by editing it. (August 2023) (Learn how and when to remove this template message) (Learn h...
Since its formation, the Swiss Air Force has used a number of different aircraft. Aircraft Current inventory A F-5E tiger II flies by at the 2012 Axalp live fire event An F/A-18C taking off from Payerne air base An AS532 Cougar helicopter Aircraft Origin Type Variant In service Notes Combat Aircraft F-5 Tiger II United States light fighter F-5E 18[1] 6 assigned to the Patrouille Suisse[2] F/A-18 Hornet United States multirole F/A-18C 25[1] F-35 Lightning II United Stat...
Neovenatoridae Rango temporal: 128 Ma PreЄ Є O S D C P T J K Pg N ↓ Cretácico InferiorPosible registro del Cretácico Superior recreación de Neovenator salerii.TaxonomíaReino: AnimaliaFilo: ChordataClase: SauropsidaSuperorden: DinosauriaOrden: SaurischiaSuborden: TheropodaInfraorden: CarnosauriaSuperfamilia: AllosauroideaFamilia: NeovenatoridaeBenson, Carrano & Brusatte, 2009Especie tipo Neovenator saleriiHutt, Martill, & Barker, 1996Géneros Neovenator Chilantaisaur...
1997 single by Thalia Mujer LatinaSingle by Thalíafrom the album Amor a la Mexicana LanguageSpanishEnglish titleLatin WomanReleased10 December 1997Recorded1997GenreLatin pop, mamboLength3:38LabelEMI LatinSongwriter(s)Kike SantanderProducer(s)Emilio Estefan Jr, Kike Santander, Bernando OssaThalía singles chronology Por Amor (1997) Mujer Latina (1997) Noches Sin Luna (1998) European CoverVengo! Vengo! (Mujer Latina) Cover Music videoMujer Latina on YouTubeEuropean Version videoVengo! Vengo! (...
1814 treaty between the UK, Sweden, and Denmark–Norway Treaty of KielKieltraktaten (Danish)Freden i Kiel (Swedish)Translated reprint of the part concerned with NorwayTypePeace treatyContextWar of the Sixth Coalition during the Napoleonic WarsSigned14 January 1814LocationKiel, Duchy of HolsteinParties United Kingdom of Great Britain and Ireland Denmark–Norway Sweden LanguageFrench The Treaty of Kiel (Danish: Kieltraktaten) or Peace of Kiel (Swedish and Norwegian: Kielfreden or fr...